Signup Crypto ETF Stocks News

Gen-Z Founder Launches Nebula - The AI Tool for the 32,000 AI Tools

SAN FRANCISCO, June 12, 2025 ( GLOBE NEWSWIRE ) -- With over 400 million people using artificial intelligence tools daily, the market for AI-driven solutions has grown rapidly - now boasting over 32,000 tools worldwide.

Source: www.benzinga.com
June 12, 2025 | 10:47:30
Category: General

Asia And Europe Markets Slide, Dollar Softens On Inflation Data And Geopolitical Worries - Global Markets Today While US Slept - SmartETFs Asia Pacific Dividend Builder ETF ( ARCA:ADIV )

Crude Oil WTI traded lower by 1.35% at $67.24/bbl, and Brent was down 1.35% at $67.47/bbl. Gold traded higher by 1.27% to $3,385.72, Silver slid 0.57% to $36.005, and Copper fell 0.37% to $4.7965. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.

Source: www.benzinga.com
June 12, 2025 | 10:49:01
Category: Markets

India's Retail Inflation falls to 2.82% in May, Lowest since February 2019 - ETCFO

India's retail inflation declined to 2.82% in May 2025, the lowest since February 2019, led by a sharp fall in food inflation to 0.99%. Both rural and urban regions saw a broad-based easing in price pressures, especially in key food categories.

Source: cfo.economictimes.indiatimes.com
June 12, 2025 | 10:54:05
Category: Economy

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg ( NX-5948 ) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ( CLL ) and Waldenström Macroglobulinemia ( WM ) - Nurix Therapeutics ( NASDAQ:NRIX )

Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses

Source: www.benzinga.com
June 12, 2025 | 10:59:59
Category: News

ANI Pharmaceuticals Announces Presentation of New Preclinical Data - ANI Pharmaceuticals ( NASDAQ:ANIP )

PRINCETON, N.J., June 12, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ANIP today announced new preclinical data on the use of Purified Cortrophin Gel ( repository corticotropin injection USP ) ( Cortrophin Gel ) in a mouse model of murine collagen-induced ...

Source: www.benzinga.com
June 12, 2025 | 10:59:59
Category: General

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology ( EULAR ) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster ...

Source: www.globenewswire.com
June 12, 2025 | 11:00:00
Category: News

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

ROCKVILLE, Md., June 12, 2025 ( GLOBE NEWSWIRE ) -- I-Mab ( NASDAQ: IMAB ) ( "I-Mab" or the "Company" ) , a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received ...

Source: www.globenewswire.com
June 12, 2025 | 11:00:00
Category: News

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach ...

Source: www.globenewswire.com
June 12, 2025 | 11:00:00
Category: News

Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

-PoNS Therapeutic Experience Program ( PoNSTEP ) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple ...

Source: www.globenewswire.com
June 12, 2025 | 11:00:00
Category: News

Syndax Presents New Revuforj® ( revumenib ) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

- 26% ( 20/77 ) CR+CRh rate and 48% ( 37/77 ) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population ...

Source: www.globenewswire.com
June 12, 2025 | 11:00:00
Category: News

© Natavest 2025 - 2026